<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognostic significance of IgH/Bcl2 rearrangement in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) remains contentious; polymerase chain reaction (PCR) methodology and tissue source variability may account for some inconsistencies </plain></SENT>
<SENT sid="1" pm="."><plain>As IgH/Bcl2 major breakpoint region (MBR) sequences may be found in <z:mpath ids='MPATH_458'>normal</z:mpath> blood, an MBR+ result by conventional PCR in blood/bone marrow may not indicate FL </plain></SENT>
<SENT sid="2" pm="."><plain>To establish <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> MBR status, 190 lymphoid tissue samples with histologically evident FL (and therefore &gt;1% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells) were examined by real-time quantifiable PCR; 50% (95/190) had clonal MBR IgH/Bcl2 (MBR was considered clonal when &gt;1%) </plain></SENT>
<SENT sid="3" pm="."><plain>Overall survival (median = 11.5 years) of MBR+ and MBR- patients was not significantly different </plain></SENT>
</text></document>